Assam Reporter

Changing Market Dynamics of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the Seven Major Markets

 Breaking News
  • No posts were found

Changing Market Dynamics of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the Seven Major Markets

May 27
22:07 2021
Changing Market Dynamics of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the Seven Major Markets

 

NMOSD Market” report has been added to DelveInsight

 

NMOSD Overview

Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).

 

NMOSD Market

DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Request free sample copy- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

 

NMOSD Market: Regions Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

NMOSD Market: Key Players

  • Alexion Pharmaceuticals
  • Viela Bio
  • Bio-Thera Solutions
  • Alexion Pharmaceuticals
  • Chord Therapeutics
  • and many others

 

NMOSD Market: Drugs

  • Soliris
  • Uplinza
  • BAT4406F
  • Ravulizumab
  • CRD1 / cladribine
  • And many others

 

NMOSD Market: Symptoms

The characteristic symptoms of NMOSD are either optic neuritis or myelitis; either may occur as the first symptom. Optic neuritis is inflammation, of the optic nerve (optic neuritis) leading to pain inside the eye which rapidly is followed by loss of clear vision (acuity). Usually, only one eye is affected (unilateral) although both eyes may be involved simultaneously (bilateral). NMOSD may or may not be preceded by a prodromal upper respiratory infection.

 

NMOSD Market: Treatment

For acute attacks, the standard treatment is high-dose intravenous corticosteroids, typically methylprednisolone. Plasma exchange may be effective in patients who experience acute severe attacks that do not respond to intravenous corticosteroids. For long-term suppression of the disease, a variety of immunosuppressive drugs are regarded by many clinicians as first-line therapy Symptom treatment may also involve the use of low doses of carbamazepine to control paroxysmal (sudden) tonic spasms that often occur during attacks of NMOSD and antispasticity agents to treat long term complication of spasticity that frequently develops in those with permanent motor deficits.

 

NMOSD Market: Disease

Greater than 95% of patients with NMOSD report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which is present in 50% of cases. NMOSD is regarded as an autoimmune disease though the exact cause for the autoimmunity is unknown.

 

NMOSD Market: Diagnosis

The uncommon disorder Neuromyelitis Optica Spectrum Disorder (NMOSD) may be difficult to interpret because of the evolving nature of diagnostic criteria, differences in the definition and accuracy of NMOSD diagnosis, the completeness of case ascertainment, and variability in assays for the disease‐specific biomarker aquaporin‐4 (AQP4)‐IgG.

 

NMOSD Market: Insights

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a heterogeneous but well-defined clinical entity, distinct from other neurologic and systemic inflammatory diseases, and treatment is poised for expansion. Treatment of NMO includes both the management of acute attacks and the prevention of future exacerbations. The goal of acute therapy is to minimize irreversible damage and accelerate recovery. Preventative therapy should lower the frequency and severity of future exacerbations.

 

 

Table of content

1. Key Insights

2. Executive Summary of Neuromyelitis Optica Spectrum Disorder (NMOSD)

3. Competitive Intelligence Analysis for Neuromyelitis Optica Spectrum Disorder (NMOSD)

4. Neuromyelitis Optica Spectrum Disorder (NMOSD): Market Overview at a Glance

5. Neuromyelitis Optica Spectrum Disorder (NMOSD): Disease Background and Overview

6. Patient Journey

7. Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment

11. Marketed Products

12. Emerging Therapies

13. Neuromyelitis Optica Spectrum Disorder (NMOSD): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Neuromyelitis Optica Spectrum Disorder (NMOSD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

What are the NMOSD Market Report Highlights?

  • In the coming years, Neuromyelitis Optica Spectrum Disorder (NMOSD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Neuromyelitis Optica Spectrum Disorder (NMOSD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Neuromyelitis Optica Spectrum Disorder (NMOSD). Launch of emerging therapies will significantly impact the Neuromyelitis Optica Spectrum Disorder (NMOSD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Neuromyelitis Optica Spectrum Disorder (NMOSD) market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder (NMOSD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder (NMOSD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder (NMOSD) market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder (NMOSD) market

Related Reports

  • NMOSD Epidemiology
  • NMOSD Pipeline

 

 About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles